Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
72,701.16
(
-0.38%
)
News Focus
News Focus
Post# of 257382
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: JohnWayne post# 161154

Wednesday, 09/04/2013 1:43:15 PM

Wednesday, September 04, 2013 1:43:15 PM

Post# of 257382
WSJ questions Algeta on valuation and Xofigo sales ramp:

http://online.wsj.com/article/SB10001424127887324202304579052760594286386.html

Xofigo's launch could be a slow burn... There may be other logistical hurdles related to Medicare reimbursement and getting physicians from different specialties like oncology and radiology to work together. An alternative to chemotherapy is surely welcome, but a radiopharmaceutical may take time to get traction with doctors and patients.

It certainly wouldn’t be the first time these issues have impeded the commercial uptake of a cancer drug.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today